Latest Articles

Publication Date
All News Scientific
Endometriosis Therapeutics Market to Reach US$ 4.05 Billion - openPR.com

Endometriosis Therapeutics Market to Reach US$ 4.05 Billion openPR.com

Published: May 5, 2026, 7:37 a.m.
Read Full Article
Emerging Sub-Segments Transforming the Digital Therapeutics Market for Endometriosis - openPR.com

Emerging Sub-Segments Transforming the Digital Therapeutics Market for Endometriosis openPR.com

Published: May 1, 2026, 1:36 p.m.
Read Full Article
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as Highly Expressed, Clinically Relevant Target for Gynecologic Cancers - National Today

Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as Highly Expressed, Clinically Relevant Target for Gynecologic Cancers National Today

Published: April 10, 2026, 4:35 p.m.
Read Full Article
Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Endometriosis Care - The National Law Review

Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Endometriosis Care The National Law Review

Published: March 24, 2026, 2:19 p.m.
Read Full Article
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis - BioSpace

EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis BioSpace

Published: March 23, 2026, 12:47 p.m.
Read Full Article
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis - PR Newswire

EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis PR Newswire

Published: March 23, 2026, 11:30 a.m.
Read Full Article
Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis - Digital Journal

Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis Digital Journal

Published: March 18, 2026, 12:41 p.m.
Read Full Article
Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis - ACCESS Newswire

Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis ACCESS Newswire

Published: March 18, 2026, 10:13 a.m.
Read Full Article
FinancialContent - Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis - FinancialContent

FinancialContent - Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis FinancialContent

Published: March 18, 2026, 10 a.m.
Read Full Article
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - The Manila Times

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update The Manila Times

Published: March 16, 2026, 12:15 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!